Lurasidone , 10mMinDMSO , 367514-87-2

CAS NO.：367514-87-2

Empirical Formula: C28H36N4O2S

Molecular Weight: 492.68

MDL number: MFCD14635357

EINECS: 696-042-8

PRODUCT Properties

• Melting point: 146-149°C
• Boiling point: 623.4±55.0 °C(Predicted)
• Density: 1.273
• storage temp.: -20°C Freezer
• solubility: Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• pka: 8.41±0.50(Predicted)
• form: Solid
• color: White to Off-White
• InChIKey: PQXKDMSYBGKCJA-CVTJIBDQSA-N
• SMILES: C1(=O)[C@]2([H])[C@@]([H])([C@]3([H])C[C@@]2([H])CC3)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(C2C3=C(SN=2)C=CC=C3)CC1

Description and Uses

The atypical antipsychotic lurasidone (also known as SM-13496) was approved in the United States in 2010 as an oral agent for the treatment of patients with schizophrenia. Lurasidone has potent affinity for D₂ (K_i= 1.7 nM) and 5-HT_2A (K_i= 2.0 nM) receptors and acts as an antagonist at both receptors. It is also a partial agonist at the 5-HT_1A receptor and, unlike other atypical agents, is a potent antagonist at the 5-HT₇ receptor; both of these activities are thought to confer beneficial cognitive properties. Lurasidone is further differentiated by its lack of affinity for muscarinic and histamine H₁ receptors and its weak affinity for the 5-HT_2C receptor. Antagonism at H₁ and 5-HT_2C receptors has been implicated in weight gain associated with atypical agents, while muscarinic receptor antagonism is associated with cognitive deficits.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P280-P305+P351+P338